GSK Clinical Trial Pipeline — 80 Active Studies

GSK (GlaxoSmithKline) pipeline at a glance (March 2026)

About the GSK (GlaxoSmithKline) clinical program

GSK's pipeline spans oncology, specialty medicines, and vaccines. In oncology, dostarlimab (Jemperli), a PD-1 inhibitor with approval in dMMR endometrial cancer, is expanding into multiple solid tumor indications. Their BCMA-targeting ADC, belantamab mafodotin (Blenrep), initially approved and then voluntarily withdrawn pending new trial data, is being re-evaluated in combination trials in multiple myeloma. In gynecologic oncology, niraparib (Zejula) for ovarian cancer is progressing through combination trials. GSK's vaccine pipeline is one of the industry's strongest — Shingrix (shingles), Arexvy (RSV), and next-generation pandemic influenza vaccines represent major development investments. In respiratory/inflammation, Nucala (mepolizumab, IL-5) is expanding across eosinophilic conditions.

Key therapeutic areas

• Oncology (PD-1, BCMA/ADC, PARP inhibitor)
• Vaccines (RSV, influenza, meningococcal)
• Respiratory / inflammation (IL-5, COPD)
• HIV (long-acting cabotegravir)
• Rare disease

Key pipeline programs

• Jemperli (dostarlimab) — PD-1, gynecologic/dMMR cancers
• Blenrep (belantamab mafodotin) — BCMA ADC, myeloma (combination trials)
• Zejula (niraparib) — PARP inhibitor, ovarian cancer
• Nucala (mepolizumab) — IL-5, eosinophilic asthma/EGPA
• Arexvy — RSV vaccine, adults 60+
• GSK3745417 — STING agonist, solid tumors

Top GSK (GlaxoSmithKline) trial indications

Condition / Indication	Trials
["Respiratory Syncytial Virus Infections"]	8
["Systemic Lupus Erythematosus"]	6
["Asthma"]	6
["Neoplasms"]	6
["Influenza, Human"]	3
["Lung Cancer, Non-Small Cell"]	3
["Pneumonia, Bacterial"]	3
["Non-alcoholic Fatty Liver Disease"]	3

Why monitor GSK (GlaxoSmithKline)'s clinical trial activity

GSK's Jemperli re-expansion program — building on the dMMR endometrial approval into broader MSI-high/dMMR tumor types and combination regimens — generates consistent new oncology registrations. Their PARP inhibitor niraparib combination trials are closely followed in gynecologic oncology. The belantamab combination re-introduction is one of the most watched programs in multiple myeloma.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to GSK (GlaxoSmithKline)'s registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks GSK (GlaxoSmithKline) trials

• Sponsor normalization: GSK (GlaxoSmithKline) may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

What is GSK's focus in oncology clinical trials?

GSK's oncology focus areas include PD-1 combinations for gynecologic and other solid tumors (Jemperli/dostarlimab), PARP inhibitor-based regimens in ovarian and other BRCA-mutated cancers (Zejula/niraparib), and belantamab mafodotin combination re-evaluation in multiple myeloma. Their STING agonist program targets solid tumor immunotherapy.

How many GSK trials are currently recruiting?

Based on current ClinicalTrials.gov data, 22 GSK-sponsored trials are actively recruiting patients across oncology, vaccines, and specialty medicine programs.

Does DataLookout cover GSK's vaccine trials?

Yes. ClinicalTrials.gov includes GSK vaccine trials registered under IND. You can monitor GSK's vaccine pipeline — RSV, influenza, and others — through DataLookout the same way as their oncology programs.